SOURCE: Actinium Pharmaceuticals

Actinium Pharmaceuticals

June 02, 2016 07:00 ET

Actinium Pharmaceuticals Applauds CancerCare® for Launching the First Ever Acute Myeloid Leukemia Awareness Month

CancerCare and Craig Sager, AML Patient and Two Time Bone Marrow Transplant Recipient, Driving Much Needed Awareness to AML Throughout the Month of June to Benefit all Patients With AML

Patient Focused Educational Event on June 17, 2016 to Include Actinium Advisory Board Member Dr. John Pagel to Discuss Bone Marrow Transplant for Patients With AML

NEW YORK, NY--(Marketwired - June 02, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of patients with advanced cancers, applauds CancerCare for their work to make June 2016 the first ever Acute Myeloid Leukemia (AML) Awareness Month. Throughout AML Awareness Month, CancerCare will feature educational information for the AML community that can be accessed via CancerCare's website (www.cancercare.org/amlaware) as well as social media efforts to raise awareness for AML.

Also, on June 17, 2016 at 1:30 pm ET, CancerCare will host a free virtual education program for patients with AML, their families and caregivers. One topic of the education program titled, "Transplantation as a Treatment Option for AML" will be led by Dr. John Pagel, MD, PhD, DSc, Chief, Hematologic Malignancies Program, Swedish Cancer Institute. Actinium's lead program, Iomab-B, is intended, upon approval, to prepare relapsed or refractory patients with AML over the age of 55 for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. Iomab-B is expected to begin a pivotal Phase 3 trial in mid-2016.

Sandesh Seth, Actinium's Executive Chairman stated, "We are thankful to have the opportunity to support AML Awareness Month and thank CancerCare for their hard work and effort in putting this together. AML is clearly an underserved disease as evidenced by the fact that no new therapies have been approved for AML patients in 40 years. With June now being AML Awareness Month we at Actinium are hopeful that this will lead to increased awareness of AML and that in turn will lead to increased funding and research to improve outcomes for patients. We ask everyone to do their part and participate in AML Awareness Month to increase drive awareness for patients, families and caregivers that make up the AML community.

About CancerCare ®

Founded in 1944, CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. CancerCare's comprehensive services include counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All CancerCare services are provided by oncology social workers and world-leading cancer experts. Headquartered in New York, NY, CancerCare maintains three additional locations in Norwalk, CT, Ridgewood, NJ and Syosset, NY.

To learn more, visit www.cancercare.org or call 800-813-HOPE (4673).

About Iomab-B

Iomab-B is about to begin the pivotal, Phase 3 SIERRA trial and is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct the single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information